Brief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
08/05/2026 14:01
May 8 (Reuters) - Alpha Tau Medical Ltd DRTS.O: ALPHA TAU COMPLETES PATIENT ENROLLMENT IN ITS U.S. PIVOTAL SKIN CANCER STUDY, ADVANCING TOWARDS GOAL OF FDA APPROVAL OF ALPHA DART® TO TREAT RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA Source text: ID:nGNX4NrP0k Further company coverage: DRTS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer